EQT Life Sciences Exits Tubulis Stake Through Gilead Sciences Deal Worth Up to $5 Billion EQT Life Sciences announces its exit from Tubulis, a German biotech firm, through a sale to Gilead Sciences for up to $5 billion, enhancing oncology innovation.

EQT Life Sciences Exits Tubulis Stake Through Gilead Sciences Deal Worth Up to $5 Billion #USA #Amsterdam #EQT_Life_Sciences #Gilead_Sciences #Tubulis

EQT Life Sciences Sells Minority Stake in Tubulis to Gilead Sciences for Major Deal EQT Life Sciences exits its minority stake in Tubulis through a significant sale to Gilead Sciences, highlighting innovative oncology platforms.

EQT Life Sciences Sells Minority Stake in Tubulis to Gilead Sciences for Major Deal #USA #Amsterdam #EQT_Life_Sciences #Gilead_Sciences #Tubulis

Tubulis: Am Ende des Weges in Akquisition durch Gilead Da halfen alle Beteuerungen und Wunschvorstellungen nicht, man wolle ein eigenständiges pharmazeutisches Unternehmen bleiben und die Pipeline kräftig voranbringen mit immer mehr Geld, das in den verga...

Mega Deal im #Pharma-Bereich:
#Gilead kauft die Martinsrieder #Tubulis mit bis zu 5 Mrd. USD.
transkript.de/artikel/2026...

Funding Raises: #ReflectionAI $2B Series B; #Oura $900M Series E; #KaileraTherapeutics $600M Series B; #Zepto $450M; #Tubulis €308M Series C; #Vantaca +$300M Growth; #Kalshi $300M Series D; #Deel $300M Series E; #Histosonics $250M; #Dexory $165M Series C; #Govini $150M Series D

Germany's Tubulis raises €308m for ADC pipeline Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.

Munich-based antibody-drug conjugate (#ADC) specialist #Tubulis has raised an impressive €308 million ($358 million) to help fund clinical trials of its cancer therapies, led by #ovariancancer candidate TUB-040.

pharmaphorum.com/news/germany...

Great talks, science, food & wine at #EFMCASMC2025 in #Porto. Advances in #SyntheticChemistry and so many new drug candidates for improving patients' lifes. Input for our efforts at #Tubulis to contribute the NextGen #ADCs to address unmet medical need. #DrugDiscovery #LifeScience #CancerResearch